These Top 2 Healthcare Companies Are in a Race to Riches
For patients who go through the rigors of daily insulin shots to treat diabetes, the costs and logistics of adhering to a scheduled plan are a lot to keep up with. When not treated properly, low blood sugar levels can sometimes lead to seizures, loss of consciousness, and death. In 2020, two top healthcare companies performed admirably during phase 2 trials in a fight to help patients better manage diabetes.
Novo Nordisk A/S (NYSE: NVO) and Eli Lilly (NYSE: LLY) both completed separate and successful phase 2 trials of new once-a-week insulin injection products that could potentially be game-changers in the insulin market for patients as well as investors. Those studies have now moved on to phase 3 trials, and if all goes well, we could see one or more new products available to consumers by 2023.
Image source: Getty Images.
Source Fool.com